Anti-nucleosome autoantibodies as markers for autoimmune hepatitis and their correlation with disease activity

Hepatology Research

Volumn 44, Issue 4, 2014, Pages 420-428

  Yokokawa, Junko ^a   Kanno, Yukiko ^a   Abe, Kazumichi ^a   Saito, Hironobu ^a   Monoe, Kyoko ^a   Katsushima, Fumiko ^a   Sakamoto, Natsumi ^a   Takahashi, Atsushi ^a   Yokokawa, Hirohide ^b   Ohira, Hiromasa ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti nucleosome antibody; Autoimmune hepatitis; Nucleosome; Relapse

Indexed keywords

AZATHIOPRINE; BILIRUBIN; IMMUNOGLOBULIN G; NUCLEOSOME ANTIBODY; PREDNISOLONE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; DRUG DOSE REDUCTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; ONSET AGE; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 84898596404     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12130     Document Type: Article

References (30)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66.
2. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-497.
3. Czaja AJ. Autoantibodies. Baillieres Clin Gastroenterol 1995; 9: 723-744.
4. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120: 239-249.
5. Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I. J Gastroenterol Hepatol 2000; 15: 1176-1182.
6. Chen M, Shirai M, Czaja AJ etal. Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 483-489.
7. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003; 48: 1658-1664.
8. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-515.
9. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-897.
10. Yoshizawa K, Matsumoto A, Ichijo T etal. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 2012; 56: 668-676.
11. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004; 37: 195-201.
12. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94: 184-192.
13. Wallace DJ, Lin HC, Shen GQ, Peter JB. Antibodies to histone (H2A-H2B)-DNA complexes in the absence of antibodies to double-stranded DNA or to (H2A-H2B) complexes are more sensitive and specific for scleroderma-related disorders than for lupus. Arthritis Rheum 1994; 37: 1795-1797.
14. Massa M, De Benedetti F, Pignatti P etal. Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 219-225.
15. Chabre H, Amoura Z, Piette JC, Godeau P, Bach JF, Koutouzov S. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38: 1485-1491.
16. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of meta-analysis. Autoimmun Rev 2012; 12: 97-106.
17. Decker P. Nucleosome autoantibodies. Clin Chim Acta 2006; 366: 48-60.
18. Tax WJ, Kramers C, van Bruggen MC, Berden JH. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 1995; 48: 666-673.
19. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999; 42: 833-843.
20. Koutouzov S, Jeronimo AL, Campos H, Amoura Z. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 2004; 30: 529-558.
21. Amoura Z, Koutouzov S, Chabre H etal. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 76-84.
22. Quattrocchi P, Barrile A, Bonanno D etal. The role of anti-nucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases. Reumatismo 2005; 57: 109-113.
23. Alvarez F, Berg PA, Bianchi FB etal. International auto-immune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
24. Tan EM, Cohen AS, Fries JF etal. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
25. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002; 35: 515-519.
26. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-1145.
27. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-627.
28. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-419.
29. Ma Y, Okamoto M, Thomas MG etal. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-664.
30. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-692.